A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Public ClinicalTrials.gov record NCT02637687. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
Study identification
- NCT ID
- NCT02637687
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Interventions
- Larotrectinib (Vitrakvi, BAY2757556) Drug
Drug
Eligibility (public fields only)
- Age range
- Up to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2015
- Primary completion
- Jul 19, 2024
- Completion
- Sep 29, 2026
- Last update posted
- Jun 21, 2025
2015 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital Los Angeles - Hematology/Oncology | Los Angeles | California | 90027 | — |
| UCLA Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095-1781 | — |
| Lucille Packard Children's Hospital Stanford - Pediatric Nephrology | Palo Alto | California | 94304 | — |
| Nemours Children's Hospital - Florida - Hematology / Oncology | Orlando | Florida | 32827 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Memorial Sloan Kettering Cancer Center New York - Main Campus | New York | New York | 10065 | — |
| Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension | Cincinnati | Ohio | 45229 | — |
| Children's Hospital of Philadelphia - Hematology/Oncology | Philadelphia | Pennsylvania | 19104 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Seattle Children's Hosptial - Oncology | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02637687, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02637687 live on ClinicalTrials.gov.